Deruxtecan (GMP)
Deruxtecan (GMP) (MC-GGFG-DXD (GMP) ) is Deruxtecan (HY-13631E) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) [1][2].
Product Specifications
CAS Number
[1599440-13-7]
Product Name Alternative
MC-GGFG-DXD (GMP)
UNSPSC
12352005
Hazard Statement
H303, H333
Target
Drug-Linker Conjugates for ADC
Related Pathways
Antibody-drug Conjugate/ADC Related
Field of Research
Cancer
Smiles
O=C(C=CC1=O)N1CCCCCC(NCC(NCC(N[C@@H](CC2=CC=CC=C2)C(NCC(NCOCC(N[C@@H]3C4=C5C(C(N6C5)=CC([C@](O)(C(OC7)=O)CC)=C7C6=O)=NC8=CC(F)=C(C)C(CC3)=C48)=O)=O)=O)=O)=O)=O
Molecular Formula
C52H56FN9O13
Molecular Weight
1034.05
Precautions
H303, H333
References & Citations
[1]NOGUCHI, Shigeru, et al. METHOD FOR SELECTIVELY MANUFACTURING ANTIBODY-DRUG CONJUGATE. WO2017002776A1.|[2]Ogitani Y, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107 (7) :1039-46.
Shipping Conditions
Dry Ice
Storage Conditions
Store in a tightly closed, dry and light-resistant container below -15°C
Scientific Category
GMP Small Molecules
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
